ORIENTBIO Inc. Total Assets
ORIENTBIO Inc. total assets. Based on the latest financial reports, ORIENTBIO Inc. (002630) holds total assets worth ₩80.37 Billion KRW (≈ $54.47 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is ORIENTBIO Inc. worth for the company's overall valuation and market capitalisation.
Total Assets of ORIENTBIO Inc. (2006–2025)
Total assets of ORIENTBIO Inc. from 2006 to 2025. This chart illustrates how ORIENTBIO Inc.'s total assets have evolved over time, based on quarterly financial data. See latest ORIENTBIO Inc. stock price today for real-time trading data and today's change.
ORIENTBIO Inc. - Asset Composition Analysis
ORIENTBIO Inc. Total Assets Breakdown (March 2025)
ORIENTBIO Inc. total assets breakdown as of March 2025. ORIENTBIO Inc.'s total assets of ₩80.37 Billion consist of 55.9% current assets and 44.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.7% |
| Accounts Receivable | ₩5.59 Billion | 6.6% |
| Inventory | ₩4.20 Billion | 5.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩99.53 Million | 0.1% |
| Goodwill | ₩1.00K | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how ORIENTBIO Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of ORIENTBIO Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ORIENTBIO Inc.'s current assets represent 55.9% of total assets in 2025, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2025, down from 14.7% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
ORIENTBIO Inc. Competitors by Total Assets
Key competitors of ORIENTBIO Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
ORIENTBIO Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.45 | 11.06 | 1.72 |
| Quick Ratio | 10.80 | 10.10 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩41.70 Billion | ₩43.65 Billion | ₩11.66 Billion |
ORIENTBIO Inc. - Advanced Valuation Insights
This section examines the relationship between ORIENTBIO Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.88 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -12.6% |
| Total Assets | ₩84.78 Billion |
| Market Capitalization | $94.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values ORIENTBIO Inc.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ORIENTBIO Inc.'s assets decreased by 12.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ORIENTBIO Inc. (2006–2025)
The table below shows the annual total assets of ORIENTBIO Inc. from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₩84.78 Billion ≈ $57.46 Million |
-12.59% |
| 2024-03-31 | ₩96.99 Billion ≈ $65.73 Million |
+19.66% |
| 2023-03-31 | ₩81.05 Billion ≈ $54.93 Million |
-22.77% |
| 2022-03-31 | ₩104.95 Billion ≈ $71.12 Million |
+46.75% |
| 2021-03-31 | ₩71.52 Billion ≈ $48.47 Million |
-0.81% |
| 2020-03-31 | ₩72.11 Billion ≈ $48.86 Million |
-14.25% |
| 2019-03-31 | ₩84.09 Billion ≈ $56.99 Million |
-55.75% |
| 2018-03-31 | ₩190.03 Billion ≈ $128.78 Million |
+10.08% |
| 2017-03-31 | ₩172.63 Billion ≈ $116.99 Million |
-1.72% |
| 2016-03-31 | ₩175.64 Billion ≈ $119.03 Million |
+18.07% |
| 2015-03-31 | ₩148.76 Billion ≈ $100.82 Million |
+6.54% |
| 2014-03-31 | ₩139.63 Billion ≈ $94.63 Million |
+2.49% |
| 2013-03-31 | ₩136.24 Billion ≈ $92.33 Million |
+10.28% |
| 2012-03-31 | ₩123.55 Billion ≈ $83.73 Million |
+45.58% |
| 2011-03-31 | ₩84.86 Billion ≈ $57.51 Million |
-18.65% |
| 2010-03-31 | ₩104.31 Billion ≈ $70.69 Million |
+6.25% |
| 2009-03-31 | ₩98.18 Billion ≈ $66.53 Million |
+18.69% |
| 2008-03-31 | ₩82.72 Billion ≈ $56.06 Million |
+13.50% |
| 2007-03-31 | ₩72.88 Billion ≈ $49.39 Million |
+6.91% |
| 2006-03-31 | ₩68.17 Billion ≈ $46.20 Million |
-- |
About ORIENTBIO Inc.
ORIENT BIO Inc. operates in the bio-industry in South Korea and internationally. It engages in the production, export, import, and life science-related research and development of laboratory animals; and offers various equipment for research environment. The company also provides infrastructural solution; health checking; generic testing; molecular biological generic testing; generic transformati… Read more